Evidence map›Paper›PMID 38179698›Full record

ArticleCirculation research2024

Sox9 Accelerates Vascular Aging by Regulating Extracellular Matrix Composition and Stiffness.

Maria Faleeva, Sadia Ahmad, Konstantinos Theofilatos, Steven Lynham, Gabriel Watson, Meredith Whitehead, Emilie Marhuenda, Thomas Iskratsch, Susan Cox, Catherine M Shanahan

Open access · hybridAbstract read
In one paragraph

Article in Circulation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
17.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 71 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Hypertensive mt. tRNARedox biology · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Piezo1 induces Wnt7bTheranostics · 2026
    Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Maria FaleevaBritish Heart Foundation (BHF) Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences (M.F., S.A., K.T., G.W., M.W., C.M.S.) King's College London, United Kingdom.ORCID 0000-0003-4774-7833
Sadia AhmadBritish Heart Foundation (BHF) Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences (M.F., S.A., K.T., G.W., M.W., C.M.S.) King's College London, United Kingdom.ORCID 0000-0002-6206-6764
Konstantinos TheofilatosBritish Heart Foundation (BHF) Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences (M.F., S.A., K.T., G.W., M.W., C.M.S.) King's College London, United Kingdom.ORCID 0000-0001-6799-0553
Steven LynhamProteomics Facility, Centre of Excellence for Mass Spectrometry (S.L.) King's College London, United Kingdom.ORCID 0000-0003-3756-6430
Gabriel WatsonBritish Heart Foundation (BHF) Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences (M.F., S.A., K.T., G.W., M.W., C.M.S.) King's College London, United Kingdom.ORCID 0009-0009-4204-7994
Meredith WhiteheadBritish Heart Foundation (BHF) Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences (M.F., S.A., K.T., G.W., M.W., C.M.S.) King's College London, United Kingdom.ORCID 0000-0002-2211-9673
Emilie MarhuendaSchool of Engineering and Material Science, Queen Mary University of London, United Kingdom (E.M., T.I.).ORCID 0000-0003-2357-9505
Thomas IskratschSchool of Engineering and Material Science, Queen Mary University of London, United Kingdom (E.M., T.I.).ORCID 0000-0002-3738-7830
Susan CoxRandall Centre for Cell & Molecular Biophysics, Faculty of Life Sciences & Medicine (S.C.) King's College London, United Kingdom.ORCID 0000-0001-8322-1981
Catherine M ShanahanBritish Heart Foundation (BHF) Centre of Research Excellence, School of Cardiovascular and Metabolic Medicine & Sciences (M.F., S.A., K.T., G.W., M.W., C.M.S.) King's College London, United Kingdom.ORCID 0000-0002-8352-8171
British Heart Foundation · GBKing's College London · GBQueen Mary University of London · GB

Funding

British Heart Foundation PG/20/6/34835British Heart Foundation RG/F/21/110064
6 · The paper itself

Abstract

backgroundVascular calcification and increased extracellular matrix (ECM) stiffness are hallmarks of vascular aging. Sox9 (SRY-box transcription factor 9) has been implicated in vascular smooth muscle cell (VSMC) osteo/chondrogenic conversion; however, its relationship with aging and calcification has not been studied.

methodsImmunohistochemistry was performed on human aortic samples from young and aged patients. Young and senescent primary human VSMCs were induced to produce ECM, and Sox9 expression was manipulated using adenoviral overexpression and depletion. ECM properties were characterized using atomic force microscopy and proteomics, and VSMC phenotype on hydrogels and the ECM were examined using confocal microscopy.

resultsIn vivo, Sox9 was not spatially associated with vascular calcification but correlated with the senescence marker p16 (cyclin-dependent kinase inhibitor 2A). In vitro Sox9 showed mechanosensitive responses with increased expression and nuclear translocation in senescent cells and on stiff matrices. Sox9 was found to regulate ECM stiffness and organization by orchestrating changes in collagen (Col) expression and reducing VSMC contractility, leading to the formation of an ECM that mirrored that of senescent cells. These ECM changes promoted phenotypic modulation of VSMCs, whereby senescent cells plated on ECM synthesized from cells depleted of Sox9 returned to a proliferative state, while proliferating cells on a matrix produced by Sox9 expressing cells showed reduced proliferation and increased DNA damage, reiterating features of senescent cells. LH3 (procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3) was identified as an Sox9 target and key regulator of ECM stiffness. LH3 is packaged into extracellular vesicles and Sox9 promotes extracellular vesicle secretion, leading to increased LH3 deposition within the ECM.

conclusionsThese findings highlight the crucial role of ECM structure and composition in regulating VSMC phenotype. We identify a positive feedback cycle, whereby cellular senescence and increased ECM stiffening promote Sox9 expression, which, in turn, drives further ECM modifications to further accelerate stiffening and senescence.

Indexed as

Muscle, Smooth, VascularVascular CalcificationAgedAgingCells, CulturedExtracellular MatrixHumansMyocytes, Smooth MuscleSOX9 Transcription FactorSOX9 protein, humanSOX9 Transcription Factoratherosclerosiscalciumextracellular matrixextracellular vesiclestranscription factors

Identifiers

PMID38179698
PMCPMC10826924
OpenAlexW4390631651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.